Efficacy News and Research

RSS

E-cigarettes share similar short-term safety profile as Nicorette products

A new study, published in the Journal of Regulatory Toxicology and Pharmacology, found that e-cigarettes share a similar short-term safety profile as Nicorette products and are comparable in reducing tobacco withdrawal symptoms.

7 Jan 2016

New report raises questions about potential risks of chromium therapies

Chromium supplements are widely consumed for their antidiabetic activity as chromium(III) enhances the insulin sensitivity of cells. In particular, orthomolecular practitioners believe in the beneficial effects of providing the body with extra amounts of essential trace elements.

6 Jan 2016

Purified cannabinoid reduces seizures in children and young adults with treatment-resistant epilepsy

Children and young adults with severe forms of epilepsy that does not respond to standard antiepileptic drugs have fewer seizures when treated with purified cannabinoid, according to a multi-center study led by researchers from UCSF Benioff Children's Hospital San Francisco.

6 Jan 2016

Modeling research shows adding a vaccine to HIV/AIDS response necessary to conclusively end the epidemic

Adding a vaccine to the comprehensive HIV/AIDS response is essential to conclusively ending the epidemic, according to modeling research published today.

6 Jan 2016

Study reveals promising mechanism for attacking Ebola virus

In late December, nearly two years after the epidemic began, the World Health Organization has declared the African country of Guinea to be free of Ebola virus infections. But, the race to find a cure and therapies to combat the disease are forging ahead as officials warn that inattention could lead to another epidemic.

5 Jan 2016

Using stem cells to tackle CNS disorders: an interview with Dr Stefano Pluchino

My laboratory’s long standing interest is the study of the signaling capabilities of stem cells, both under homeostatic conditions

From Beckman Coulter Life Sciences - Flow Cytometry 5 Jan 2016

New phase III trial takes intravaginal DHEA a step closer to approval

A new phase III trial with positive results is taking intravaginal DHEA a step closer to governmental approval. The formulation could provide women who cannot or do not wish to use intravaginal estrogen with an effective vaginal alternative for easing vaginal symptoms and pain with sex after menopause.

5 Jan 2016

Drug-microbe interactions may contribute to adverse effects, lessen effectiveness of NSAID

A nonsteroidal anti-inflammatory drug (NSAID) changed the composition and diversity of gut microbes, which in turn shaped how the drug is broken down and ultimately, cut its effectiveness, according to an animal study from the Perelman School of Medicine at the University of Pennsylvania.

5 Jan 2016

UVA-developed artificial pancreas system to undergo final testing in two clinical trials

A device developed by University of Virginia School of Medicine researchers to automatically monitor and regulate blood-sugar levels in people with type 1 diabetes will undergo final testing in two clinical trials beginning in early 2016.

5 Jan 2016

Researchers to undertake long-term clinical trial of artificial pancreas system for type 1 diabetes patients

Researchers will soon undertake one of the largest-ever long-term clinical trials of a system designed to help regulate blood sugar levels of individuals with type 1 diabetes mellitus. If the so-called artificial pancreas system performs in patients as hoped, it could lead to commercial trials and eventual regulatory approval in the United States and abroad.

5 Jan 2016

Bayer to present new research findings on Xofigo (radium Ra 223 dichloride) injection at ASCO GU 2016

Bayer announced today that new research findings on Xofigo (radium Ra 223 dichloride) injection will be presented at the 2016 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU) taking place January 7 – 9 in San Francisco.

4 Jan 2016

First patient enrolled in Phase 3 efficacy trial of CAM2038 for opioid dependence

Braeburn Pharmaceuticals and Camurus announce that the first patient has been randomized in the double blind Phase 3 efficacy trial of CAM2038 in opioid-dependent patients. CAM2038 medications are designed for long-acting weekly and monthly administration.

31 Dec 2015

New oral breast cancer drug has potential to combat other types of cancer

Palbociclib, a new oral drug whose efficacy in combating breast cancer has been demonstrated alone and in combination with endocrine therapy, also has potential to combat other types of cancer, according to a literature review and additional original research conducted by experts at the Abramson Cancer Center in the University of Pennsylvania published this month in JAMA Oncology.

30 Dec 2015

Delivering novel formulation of propranolol as liquid salt may reduce skin toxicity

Formulating drugs as liquid salts may provide a safe and efficient strategy for topical delivery of drugs that cause skin toxicity. A team of researchers from the University of California, Santa Barbara (UCSB) in Santa Barbara, CA has demonstrated a novel formulation of propranolol as a liquid salt which enables delivery through skin with reduced toxicity.

30 Dec 2015

Discovery Laboratories initiates AEROSURF phase 2b clinical trial in premature infants with RDS

Discovery Laboratories, Inc., a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has initiated its AEROSURF phase 2b clinical trial in premature infants 26 to 32 weeks gestational age (GA) receiving non-invasive nasal continuous positive airway pressure (nCPAP) for respiratory distress syndrome (RDS).

29 Dec 2015

Several therapies for hemophilia A, hemophilia B and hemophilia with inhibitors to be launched between 2015-2025

Decision Resources Group forecasts that several therapies will launch for hemophilia A, hemophilia B and hemophilia with inhibitors in the United States and Europe during our 2015-2025 study period.

29 Dec 2015

Rich Pharmaceuticals obtains FDA approval to begin Phase 1/2 study in AML and MDS patients

Rich Pharmaceuticals, Inc. is pleased to announce that the Company has received approval from the U.S. Food and Drug Administration to commence its Phase 1/2 clinical for the treatment of Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients.

28 Dec 2015

Study shows why immune system fails to develop immunity during malaria infection

Australian scientists have for the first time revealed how malaria parasites cause an inflammatory reaction that sabotages our body's ability to protect itself against the disease.

26 Dec 2015

Azithromycin remains effective in treatment of urogenital chlamydia, confirms UAB study

In one of the most tightly controlled trials ever conducted of drugs used to treat sexually transmitted infections, researchers at the University of Alabama at Birmingham have confirmed that azithromycin remains effective in the treatment of urogenital chlamydia.

24 Dec 2015

Positive interim results from TWIB's AC-201 CR Phase 2 study for hyperuricemia and gout

TWi Biotechnology Inc. today announced interim results from the ongoing Phase 2 proof of concept clinical study evaluating AC-201 CR as an oral uricosuric and anti-inflammatory agent for the treatment of hyperuricemia and prevention of gout flares combining with febuxostat, a xanthine oxidase inhibitor.

24 Dec 2015

Efficacy News and Research

E-cigarettes share similar short-term safety profile as Nicorette products

New report raises questions about potential risks of chromium therapies

Purified cannabinoid reduces seizures in children and young adults with treatment-resistant epilepsy

Modeling research shows adding a vaccine to HIV/AIDS response necessary to conclusively end the epidemic

Study reveals promising mechanism for attacking Ebola virus

Using stem cells to tackle CNS disorders: an interview with Dr Stefano Pluchino

New phase III trial takes intravaginal DHEA a step closer to approval

Drug-microbe interactions may contribute to adverse effects, lessen effectiveness of NSAID

UVA-developed artificial pancreas system to undergo final testing in two clinical trials

Researchers to undertake long-term clinical trial of artificial pancreas system for type 1 diabetes patients

Bayer to present new research findings on Xofigo (radium Ra 223 dichloride) injection at ASCO GU 2016

First patient enrolled in Phase 3 efficacy trial of CAM2038 for opioid dependence

New oral breast cancer drug has potential to combat other types of cancer

Delivering novel formulation of propranolol as liquid salt may reduce skin toxicity

Discovery Laboratories initiates AEROSURF phase 2b clinical trial in premature infants with RDS

Several therapies for hemophilia A, hemophilia B and hemophilia with inhibitors to be launched between 2015-2025

Rich Pharmaceuticals obtains FDA approval to begin Phase 1/2 study in AML and MDS patients

Study shows why immune system fails to develop immunity during malaria infection

Azithromycin remains effective in treatment of urogenital chlamydia, confirms UAB study

Positive interim results from TWIB's AC-201 CR Phase 2 study for hyperuricemia and gout

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News